{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dexamethasone phosphate
to a specific field?
Status:
Investigational
Source:
NCT04553406: Phase 2 Interventional Terminated Mycobacterium Avium Complex
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:dazdotuftide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:bexotegrast [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04402489: Phase 3 Interventional Completed EPP
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01225536: Phase 1 Interventional Completed Solid Tumor
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:emavusertib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03428958: Phase 1/Phase 2 Interventional Completed Colorectal Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00725933: Phase 1 Interventional Completed Advanced Solid Tumors
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01466322: Phase 1 Interventional Completed Multiple Sclerosis, Relapsing-Remitting
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00482287: Phase 2 Interventional Withdrawn Hypotension
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104 (MTR- 105), is a nitric oxide synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity. MTR-105, a
fast-acting synthetic NOS inhibitor with rapid onset of action when administered parenterally, has
been effective in alleviating hypotension experimentally
and in several observational studies while reducing NO
production. MTR-105 is registered and approved for clinical use in the Republic of Moldova where data have been
collected from 434 patients exposed to the drug in pre- and postapproval clinical investigations.
